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ISSNObjectives: To conduct two economic analyses addressing whether to: routinely
monitor HIV-infected children on antiretroviral therapy (ART) clinically or with labora-
tory tests; continue or stop cotrimoxazole prophylaxis when children become stabilized
on ART.
Design and methods: The ARROW randomized trial investigated alternative strategies
to deliver paediatric ART and cotrimoxazole prophylaxis in 1206 Ugandan/Zimbab-
wean children. Incremental cost-effectiveness and value of implementation analyses
were undertaken. Scenario analyses investigated whether laboratory monitoring (CD4þ
tests for efficacy monitoring; haematology/biochemistry for toxicity) could be tailored
and targeted to be delivered cost-effectively. Cotrimoxazole use was examined in
malaria-endemic and non-endemic settings.
Results: Using all trial data, clinical monitoring delivered similar health outcomes to
routine laboratory monitoring, but at a reduced cost, so was cost-effective. Continuing
cotrimoxazole improved health outcomes at reduced costs. Restricting routine CD4þ
monitoring to after 52 weeks following ART initiation and removing toxicity testing was
associated with an incremental cost-effectiveness ratio of $6084 per quality-adjusted
life-year (QALY) across all age groups, but was much lower for older children
(12þ years at initiation; incremental cost-effectiveness ratio¼$769/QALY). Commit-
ting resources to improve cotrimoxazole implementation appears cost-effective. A
healthcare system that could pay $600/QALY should be willing to spend up to
$12.0 per patient-year to ensure continued provision of cotrimoxazole.
Conclusion: Clinically driven monitoring of ART is cost-effective in most circum-
stances. Routine laboratory monitoring is generally not cost-effective at current prices,
except possibly CD4þ testing amongst adolescents initiating ART. Committing
resources to ensure continued provision of cotrimoxazole in health facilities is more
likely to represent an efficient use of resources.
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Despite large funding increases for HIV/AIDS pro-
grammes in developing countries over the past decade,
the availability of paediatric antiretroviral therapy (ART)
lags behind that for adults. In the region most affected
by HIV/AIDS – sub-Saharan Africa – only 32% of
1.6 million children in need of ART in 2013 received it
[1]. A priority for HIV/AIDS programmes must be to
reduce this large treatment gap. Economic studies can
help identify how limited available resources can be cost-
effectively used to meet the health needs of HIV-infected
children.
The Anti-Retroviral Research for Watoto (ARROW)
trial (ISRCTN24791884) was a large, long-term strategy
trial in children starting ART in Africa. The two
randomizations considered here showed that: routine
3-monthly CD4þ monitoring provided some health
benefit over clinical monitoring, but only after the first
year on ART; however, event rates were low, survival was
high and monitoring for toxicity offered no benefit [2];
continuous cotrimoxazole prophylaxis significantly
reduced hospitalizations for malaria and other infections
among children aged above 3 years and who were stable
on ART [3].
This study uses clinical effectiveness and resource-use data
collected in the trial to investigate strategies for monitoring
children on ART and use of cotrimoxazole prophylaxis,
with the aim of identifying potential efficiency gains in
paediatric HIV programmes to maximize health outcomes
from limited available resources.Methods
Trial summary and clinical effectiveness
In this trial, 1206 previously untreated HIV-infected
children/adolescents meeting WHO 2006 criteria [4] for
ART initiation were enrolled from three centres in
Uganda (Joint Clinical Research Centre, Kampala;
Paediatric Infectious Diseases Clinic/Baylor Uganda,
Mulago; MRC/UVRI Uganda Research Unit on AIDS,
Entebbe) and one in Zimbabwe (University of Zimbabwe
Clinical Research Centre, Harare).
For the monitoring randomization, all 1206 children
were randomized to laboratory and clinical monitoring
(LCM; 12-weekly CD4þ, haematology, biochemistry) or
clinically driven monitoring (CDM; no CD4þ, haema-
tology/biochemistry, if needed, for clinical management).
Median follow-up [inter-quartile range (IQR)] was
4.0 years (3.7–4.4) and only 3% were lost to follow-
up/withdrew consent (i.e. were last seen before the study
end and were not known to have died) [2]. For the
cotrimoxazole prophylaxis randomization, 1012 children Copyright © 2015 Wolters Kluwer H(>3 years) on ART for more than 96 weeks following
enrolment to the monitoring trial were approached for
randomization (61 had died, were lost to follow-up or
withdrew; 113 were not approached). Two hundred and
fifty-two children were not randomized, mostly because
their caregivers strongly believed cotrimoxazole was
beneficial. Seven hundred and fifty-eight were random-
ized to continue or stop contrimoxazole and were
followed for a median of 107 weeks (96–117); less than
1% were lost to follow-up [3].
In the monitoring randomization, the primary endpoint
(first WHO 4 event/death) rate was lower in the first year
on ART in the CDM group than in the LCM group (4.1
vs. 5.8/100 child years; P¼ 0.2) [2]. However, this was
likely due to chance because neither group was switched
to second-line ART before 48 weeks. In contrast, in years
2–5, WHO 4/death rates were significantly higher in the
CDM than in the LCM group (1.3 vs. 0.4/100 child
years; P¼ 0.002), suggesting benefit of 3-monthly CD4þ
monitoring in the LCM group. Adverse events and ART
substitutions for toxicity were infrequent and similar in
both groups.
Children stopping cotrimoxazole after 96 weeks on ART
had significantly higher rates of hospitalization/death
compared to those continuing cotrimoxazole [hazard
ratio 1.64, 95% confidence interval (CI) 1.14, 2.37,
P¼ 0.007], but mortality was low and similar in both
groups. Increased hospitalizations in the stop-cotrimox-
azole group were for infections (such as pneumonia,
meningitis and sepsis) and malaria. Significant differences
in hospitalization/death were evident at even the highest
CD4þ values and were similar in Uganda and Zimbabwe
(despite differences in malaria endemicity), across all ages
and in both monitoring arms [3].
Ethics approval was received for the economics study in
Uganda by the National Council for Science and
Technology and the Institutional Review Boards of
Joint Clinical Research Council and Baylor College of
Medicine; and in Zimbabwe by the Medical Research
Council Institutional Review Board.
Cost and outcome estimation
Healthcare costs were estimated taking a health system
perspective using the ‘ingredients’ approach [5].
Resource use data were collected on case report forms
in the ARROW trial on nurse/doctor visits (routine and
non-routine), antiretroviral drugs, other/concomitant
medications, monitoring tests (CD4þ cell count,
biochemistry, haematology), radiographs and blood
transfusions; items not expected to be incurred for
roll-out of interventions were omitted.
Resource-use items from the ARROW centres in
Zimbabwe/Uganda and representative national unit
costs/prices were combined to estimate the total costsealth, Inc. All rights reserved.
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costings undertaken as part of the Development of Anti-
Retroviral Therapy in Africa (DART) trial [6], which
compared LCM vs. CDM in adults at the same centres
where the ARROW trial was conducted. Results were
qualitatively similar across sites, and pooled results are
presented for a typical sub-Saharan African country using
the 2012 prices.
Outcomes were evaluated in terms of quality-adjusted
life-years (QALYs), a generic measure combining both
mortality and morbidity effects of interventions [5] (main
text) and life-years gained (online supplement, http://
links.lww.com/QAD/A602). As there are currently no
published QALY weights for HIV-infected children in
Africa, we used results from a model of health state
utilities for HIV-infected adults in high-income countries
(see eTable one for details, http://links.lww.com/QAD/
A602) [7,8].
Resource use, costs and health outcomes (QALYs) were
estimated per 6-month time-period over 228 weeks
(4.4 years) and 104 weeks (2.0 years) from the monitoring
and cotrimoxazole randomizations, respectively. This
time-point was chosen to ensure all WHO 4 events/
deaths were included, and that most children had
complete data over the follow-up period. Missing data
for costs and QALYs, due to unavailable CD4þ tests
within a 6-month period, loss to follow-up before the
trial end, or when trial closure was before children
reached 228 or 104 weeks follow-up, respectively, were
estimated using multiple imputation by chained equations
using predictive mean matching [9]. Mean CD4þ% was
used to estimate QALYs when there were multiple
CD4þ% values within a 6-month period.
The expected lifetime cost and health outcomes for
sub-Saharan African children alive and on ART are still
largely unknown. To estimate the long-term impacts of
interventions, in a further analysis, we assumed those alive
at trial end live for another 25 years, resulting in an
additional 13.93 discounted QALYs (assumed QALY
weight of 0.8; discounted at 3% per annum) and incur
costs after the trial end of $200 per year (much lower than
current costs of providing paediatric ART; discounted at
3%), regardless of the randomization strategy [10]. This
scenario can be considered as representing the maximum
potential for the more effective, more expensive altern-
atives to be cost-effective in the long term.
Monitoring strategies (cost-effectiveness
analysis)
For the monitoring strategies it was anticipated the more
effective alternative (LCM) would be more costly than the
less effective alternative (CDM). Cost-effectiveness was
estimated by comparing incremental cost-effectiveness
ratios (ICERs – the additional cost per QALY gained) of
LCM vs. CDM, to a cost-effectiveness threshold [5]. Copyright © 2015 Wolters KluweThe cost-effectiveness threshold represents the opportu-
nity costs of committing resources to fund interventions
in terms of health gains forgone due to resources being
unavailable for the provision of alternative investments
[11]. It is, therefore, crucial to have a reasonable estimate
of the threshold as a basis to determine whether an
intervention offers value for money in a particular
healthcare system.
To capture uncertainty, results are estimated probabil-
istically and, for some scenarios, are presented across a
range of cost-effectiveness thresholds in the form of cost-
effectiveness acceptability curves (CEACs) [12]. These
show the probability that an alternative is cost-effective at
different levels of the threshold based upon modelled
variation in patient outcomes observed.
It is challenging to assess how low ICERs should be for
interventions to represent cost-effective use of finite
healthcare resources. The WHO deem an intervention
offering a unit of health gain (DALY-averted) at under
three times gross domestic product (GDP) per capita to be
‘relatively cost-effective’ and less than GDP per capita
‘highly cost-effective’ [13]. In 2009, GDP per capita was
estimated to be US$523 in Uganda and US$324 in
Zimbabwe [14], resulting in upper thresholds of
US$1569 in Uganda and US$972 in Zimbabwe.
However, GDP-based thresholds do not adequately
reflect opportunity costs, and a number of commentators
believe the WHO-recommended thresholds are too high
[15].
An alternative is to assess other ways in which resources
can be used to generate health gains in the population. In
situations when HIV treatment coverage gaps remain for
both adult and paediatric ART, one option is to compare
estimated ICERs with those estimated in other studies for
the provision of ARTwith clinical monitoring versus no
ART because resources could instead be used to close the
ART coverage gap. Other studies have estimated these at
$600/QALY [16], $590/LYG [17] and $628/QALY [18]
for adults. In this study, we therefore choose to assess
ICERs against a benchmark of $600 to determine
whether there is a possibility the interventions may be
cost-effective relative to widening ART provision.
A number of scenario analyses were undertaken to
investigate conditions under which the interventions
are more likely to be cost-effective. These included:
restricting trial resource use and event data to after week
12 (from when the first routine measurements in LCM
occurred) and week 52 (after which LCM was shown to
be more effective, amounting to a strategy of introducing
laboratory monitoring after 1 year on ART); removing
the costs of toxicity monitoring that had no impact on
adverse event outcomes and undertaking age sub-group
analyses (<3, 3–6, 7–11 and 12þ years) to allow the
youngest children, preadolescents and adolescents to ber Health, Inc. All rights reserved.
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monitoring costs will decrease in the future, as point-
of-care alternatives become available, so we also
investigated how a 50% reduction in CD4þ monitoring
costs would affect cost-effectiveness.
Cotrimoxazole strategies (value of
implementation analysis)
A cost-effectiveness analysis was undertaken to compare
continuing versus stopping cotrimoxazole prophylaxis
once children are stabilized on ART. However, since
cotrimoxazole is low-cost even within the context of sub-
Saharan Africa, it was expected that continuation would
be cost-effective. Despite its low cost and attempts to
ensure widespread provision, frequent stock-outs in
health facilities have nevertheless been reported [19],
indicating failure of health systems to deliver cotrix-
imoxazole reliably to patients. This suggests that further
interventions (depending on context) may be beneficial
to improve implementation. Possible options include
strengthening procurement systems [20,21], improving
drug supply chains and tracking systems [22] or paying
providers based on provision of cotrimoxazole [23].
Most initiatives to improve implementation will require
financial investment and policymakers must consider the
resources they might commit within the context of other
competing calls on their budgets. A value of imple-
mentation analysis was undertaken to investigate under
what conditions such implementation initiatives are likely
to prove worthwhile [24,25]. A cost-effectiveness
threshold of $600 was assumed to reflect the opportunity
costs of healthcare resources (described previously). An
upper bound for how much policymakers should be
willing to spend to ensure continuous cotrimoxazole
prophylaxis to children on ART was estimated using
the measure of incremental net monetary benefit
[(difference in QALYS threshold) difference in costs]
(see eMethods for a full explanation). Importantly, grade
3/4 toxicity did not differ in the continue/stop
cotrimoxazole arms of the trial. This analysis represents
a conservative estimate of the value of improving Copyright © 2015 Wolters Kluwer H
Table 1. Unit costs/prices.
Resource item Unit cost/price
Nurse visits (routine) $4.59 (Entebbe), $3.71 (JCR
Doctor visits (routine) $4.59 (Entebbe), $3.71 (JCR
Other healthcare visits $3.67 (Entebbe), $9.95 (JCR
Antiretroviral therapy costs Various (costed individually
regimens – see eTable2,
Concomitant medications Various (costed individually
(see eTable 3, http://links.
Hospitalizations (per inpatient day) $34.95 (all centres)
CD4þ tests $17.77 (Entebbe), $11.33 (JC
Haematology panel tests $7.27 (Entebbe), $8.02 (JCR
Biochemistry panel tests $13.12 (Entebbe), $12.01 (JC
Radiographs $7.19 (all centres)
Blood transfusions $20.02 (all centres)
JCRC, Joint Clinical Research Centre; PIDC, Pediatric Infectious Diseasescotrimoxazole implementation because external benefits
in terms of supply of other drugs, including to other
patient groups, are also likely to occur.Results
Resource-use items associated unit costs/prices are
presented in Table 1 (see eTables 2 and 3, http://
links.lww.com/QAD/A602 for antiretroviral and other/
concomitant medication units costs/prices).
Monitoring strategies
Estimated total costs, QALYs and ICERs are presented by
monitoring strategy in Table 2, relating to the period of
trial follow-up. Estimates are based upon imputed values
when data are missing (see eTable 4 on missing data,
http://links.lww.com/QAD/A602). Counts of resource
use and disaggregated costs, based on available case data,
are provided in eTables 5 and 6 (http://links.lww.com/
QAD/A602).
Using all data from initial randomization through patient
follow-up to 228 weeks, the mean total costs of delivering
ART with LCM ($2327.9) were greater than that with
CDM ($1775.3). LCM offered fewer QALYs (3.9 vs.
4.0), predominantly because of the early imbalance in
deaths (27 LCM vs. 13 CDM in the first year on ART).
CDM therefore ‘dominated’ LCM, being more effective
and less costly, and LCM was not cost-effective.
Restricting the analysis from 12 weeks after ART
initiation to 228 weeks, mean total costs per patient
were $2132.9 (LCM) and $1608.8 (CDM); driven
overwhelmingly by higher monitoring costs with LCM
($647 vs. $19 CDM), representing 30% of total costs in
the LCM strategy (eTable 6, http://links.lww.com/
QAD/A602). More than half of this cost derived from
routine laboratory monitoring for toxicity (haematology/
biochemistry) which was shown to have no benefit [2].ealth, Inc. All rights reserved.
Source
C), $9.43 (Harare), $3.71 (PIDC) [6]
C), $9.43 (Harare), $3.71 (PIDC) [6]
C), $9.83 (Harare), $9.95 (PIDC) [6]
, by patient, based upon length of time on
http://links.lww.com/QAD/A602)
[26]
, by patient, based on non-ART drug prescriptions
lww.com/QAD/A602)
[27]
[7]
RC), $18.82 (Harare), $11.33 (PIDC) [6]
C), $13.87 (Harare), $11.33 (PIDC) [6]
RC), $13.76 (Harare), $12.01 (PIDC) [6]
[7]
[27]
Clinic.
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Table 2. Results (base case and alternative uses of laboratory monitoring).
LCM CDM
Base case: using all trial data from randomization (week 0) to 228 weeks
Costs, mean (SD), US$ 2327.9 (24.6) 1775.3 (20.1)
QALYs, mean (SD) 3.9 (.03) 4.0 (.02)
Incremental cost-effectiveness ratio (ICER) CDM dominates
Evaluated from 12 weeks after initial randomization to 228 weeks
Costs, mean (SD), US$ 2132.9 (20.2) 1608.8 (18.5)
QALYs, mean (SD) 3.80 (.02) 3.79 (.02)
Incremental cost-effectiveness ratio (ICER) $49497/QALY
Evaluated from 12 weeks after initial randomization to 228 weeks; excluding toxicity testing
Costs, mean (SD), US$ 1815.0 (17.7) 1592.3 (18.0)
QALYs, mean (SD) 3.80 (.02) 3.79 (.02)
Incremental cost-effectiveness ratio (ICER) $21023/QALY
Evaluated from 52 weeks after initial randomization
Costs, mean (SD), US$ 1659.4 (14.4) 1243.2 (14.1)
QALYs, mean (SD) 3.2 (.00) 3.1 (.01)
Incremental cost-effectiveness ratio (ICER) $13896/QALY
Evaluated from 52 weeks after initial randomization; excluding toxicity tests
Costs, mean (SD), US$ 1412.9 (12.8) 1230.6 (13.7)
QALYs, mean (SD) 3.2 (.00) 3.1 (.01)
Incremental cost-effectiveness ratio (ICER) $6084/QALY
Evaluated from 52 weeks after initial randomization; excluding toxicity tests and with 50% reduction in CD4þ monitoring costsa
Costs, mean (SD), US$ 1303.5 (12.4) 1230.6 (13.7)
QALYs, mean (SD) 3.2 (.00) 3.1 (.01)
Incremental cost-effectiveness ratio (ICER) $2431/QALY
CDM, clinically driven monitoring; ICER, incremental cost-effectiveness ratio; LCM, laboratory and clinical monitoring; QALY, quality-adjusted
life-year. Results are based upon multiple imputation by chained equations using predictive mean matching [9], where cost and QALY data per
period of analysis are missing assumed at random. aBase case ‘fully loaded’ CD4þ test costs are $17.8 in Entebbe, $11.3 in JCRC/PIDC, $18.8 in
Harare. The 50% reduction on these fully loaded costs results in CD4þ test costs of $8.9 in Entebbe, $5.7 in JCRC/PIDC, $9.4 in Harare.Mean QALYs were 3.80 (LCM) and 3.79 (CDM),
leading to an ICER per QALY of $49 497.
In weeks 52–228, mean total costs and QALYs were
$1659 and 3.16 (LCM) vs. $1243 and 3.13 (CDM),
leading to an ICER per QALY of $13 896. Removing
toxicity tests led to ICERs of $21 023 and $6084 in weeks
12–228 and 52–228, respectively.
In weeks 52–228, after removing toxicity tests, the
ICERs in those initiating ART aged below 3, 3–6, 7–11
and 12þ years were $26101, $6277, $5093 and $769,
respectively (see Table 3). If, in a future scenario, the costs
of CD4þ monitoring were to fall by 50% (to $9.4 in
Zimbabwe and $7.3 in Uganda; ‘full loaded’ costs
reflecting capital costs and personnel time as well as
consumables), these ICERs would fall to $11 697, $2251,
$2248 and LCM (without toxicity tests) dominating
CDM, respectively (see eTables 7 and 8, http://
links.lww.com/QAD/A602 for results using the measure
of life-years gained).
Cost-effectiveness acceptability curves, based on costs and
health outcomes in weeks 52–228, are presented in
Fig. 1, for the two selected scenarios for which routine
laboratory monitoring is more likely to be cost-effective
for some healthcare systems: removing costs of toxicity
testing, for all trial participants; removing costs of toxicity
testing and reducing costs of CD4þ testing by 50%, for all
trial participants and by age sub-groups. These show that
LCM is very unlikely to be cost-effective at thresholds Copyright © 2015 Wolters Kluwebelow $2000, overall and within sub-groups, with the
exception of CD4þ testing alone for adolescents (aged
12þ), especially when testing costs are reduced.
Including increments for additional QALYs and costs for
children alive at trial end led to ICERs for introducing
routine CD4þ monitoring from 52 weeks, without
toxicity testing, for ages below 3, 3–6, 7–11 and 12þ
years of $2728, $957, $680 and $319 per QALY,
respectively (see eTable 9, http://links.lww.com/QAD/
A602).
Cotrimoxazole strategies
Continuing cotrimoxazole for children on long-term
ART led to persistent reductions in hospitalizations and
prescriptions of non-ART drugs, with accompanying
reductions in costs that exceeded the costs of providing
cotrimoxazole itself. Stopping cotrimoxazole is both
more costly and less effective than continued provision, so
is not cost-effective.
Using all available trial data, mean total health sector costs
and QALYs over 104 weeks follow-up were $947.3 and
1.867 (stopping) vs. $926.5 and 1.872 (continuing)
(Table 4). The main driver of higher costs with stopping
cotrimoxazole was hospitalization costs ($43 with stop-
ping, $24 with continuing), estimated based upon available
use data (see eTables 10 and 11, http://links.lww.com/
QAD/A602). The cost reduction was similar in both
Uganda ($21), a malaria-endemic country, and Zimbabwe
($18), a non-malaria-endemic country.r Health, Inc. All rights reserved.
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Table 3. Cost-effectiveness results of laboratory monitoring strategies (age sub-group analyses).
LCM CDM
Age sub-group analyses; evaluated from 52 weeks after initial randomization, no toxicity monitoring
Under 3-year-olds
Costs, mean (SD), US$ 1392.1 (19.8) 1191.5 (16.6)
QALYs, mean (SD) 3.17 (.00) 3.16 (.01)
Incremental cost-effectiveness ratio (ICER) $26101/QALY
3–6-year-olds
Costs, mean (SD), US$ 1392.2 (19.2) 1224.9 (18.3)
QALYs, mean (SD) 3.2 (.00) 3.1 (.01)
Incremental cost-effectiveness ratio (ICER) $6277/QALY
7–11-year-olds
Costs, mean (SD), US$ 1459.6 (22.2) 1257.3 (19.9)
QALYs, mean (SD) 3.2 (.01) 3.1 (.02)
Incremental cost-effectiveness ratio (ICER) $5093/QALY
12þ-year-olds
Costs, mean (SD), US$ 1340.7 (34.0) 1282.4 (49.8)
QALYs, mean (SD) 3.14 (.01) 3.07 (.06)
Incremental cost-effectiveness ratio (ICER) $769/QALY
Age sub-group analyses; evaluated from 52 weeks after initial randomization, no toxicity monitoring and fully loaded CD4þ monitoring
costs reduced by 50%a
Under 3-year-olds
Costs, mean (SD), US$ 1281.4 (19.3) 1191.5 (16.6)
QALYs, mean (SD) 3.17 (.00) 3.16 (.01)
Incremental cost-effectiveness ratio (ICER) $11697/QALY
3–6-year-olds
Costs, mean (SD), US$ 1284.9 (18.3) 1224.9 (33.6)
QALYs, mean (SD) 3.2 (.00) 3.1 (.01)
Incremental cost-effectiveness ratio (ICER) $2251/QALY
7–11-year-olds
Costs, mean (SD), US$ 1346.6 (21.3) 1257.3 (19.9)
QALYs, mean (SD) 3.2 (.01) 3.1 (.02)
Incremental cost-effectiveness ratio (ICER) $2248/QALY
12þ-year-olds
Costs, mean (SD), US$ 1247.1 (37.3) 1282.4 (49.8)
QALYs, mean (SD) 3.14 (.01) 3.07 (.06)
Incremental cost-effectiveness ratio (ICER) LCM (without toxicity) dominates
CDM, clinically driven monitoring; ICER, incremental cost-effectiveness ratio; LCM, laboratory and clinical monitoring; QALY, quality-adjusted
life-year. Results are based upon multiple imputation by chained equations using predictive mean matching, [9] where cost and QALY data per
period of analysis are missing assumed at random. aBase case ‘fully loaded’ CD4þ test costs are $17.8 in Entebbe, $11.3 in JCRC/PIDC, $18.8 in
Harare. The 50% reduction on these fully loaded costs results in CD4þ test costs of $8.9 in Entebbe, $5.7 in JCRC/PIDC, $9.4 in Harare.The incremental net monetary benefit (INMB) for
continuous provision of cotrimoxazole depends upon the
cost-effectiveness threshold. At a threshold of $600,
INMB per patient is $24 over 2 years of trial follow-up; or
equivalently $12 per patient-year. This means that if
policymakers can ensure that cotrimoxazole is provided
by use of some implementation initiative costing below
$12 per patient-year (over and above the estimated $6.51
per patient-year procurement cost of cotrimoxazole
[28]), this would represent value for the health system.
This indicates health systems should be willing to invest
notable resources to improve continuity of cotrimoxazole
provision (e.g. in a district with 2000 children on ARTan
investment of up to $24 000 would be worthwhile).Discussion
Healthcare systems in sub-Saharan Africa are severely
resource-constrained and cannot meet all the health needs
of HIV-infected children. Policymakers must make Copyright © 2015 Wolters Kluwer Hdifficult decisions as how best to use available resources
to generate health gains. Paediatric ART is just one
intervention competing for resources; other interven-
tions, such as those aimed at HIV prevention (including
from mother to child), HIV diagnosis and also non-HIV
health interventions, hold equally important claims.
Ensuring efficient provision of paediatric ART is
important because it ensures resources committed to
paediatric HIV treatment are used to greatest effect.
The study uses data from the ARROW trial to inform
when efficiencies may be gained in tailoring paediatric
ART programmes. A randomized trial design has
advantages compared to other (i.e. observational) data
sources since the design removes confounding and
selection bias giving results strong internal validity. The
trial showed that CDM (no CD4þ, haematology/
biochemistry, if needed, for clinical management) delivers
impressive health outcomes similar to those achieved with
routine LCM (12-weekly CD4þ, haematology, bio-
chemistry), which provided only small additional health
gain at substantial additional cost. Conversely, continuedealth, Inc. All rights reserved.
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
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LCM dominates CDM
it is more effective, and less costly
(a) CEAC: all trial participants, with no toxicity monitoring (b) CEAC: all trial participants, with no toxicity monitoring
and half CD4+ test costs
(d) 3 to 6 year olds (c) Under 3 year olds
(d) 7 to 11 year olds (e) 12+ year olds
CEACS with no toxicity monitoring (a), and no toxicity monitoring and half CD4 costs
CEACS with no toxicity monitoring and half CD4+ costs: age subgroup analyses
Fig. 1. Cost-effectiveness acceptability curves of alternative approaches to monitoring. (a) LCM, laboratory and clinical
monitoring (12-weekly CD4þ, haematology, biochemistry). CDM, clinically driven monitoring (no CD4þ; haematology/bio-
chemistry, if needed, for clinical management). ICER, incremental cost-effectiveness ratio (the cost per QALY-gained from LCM
compared to CDM). The ‘cost-effectiveness threshold’ represents the maximum a healthcare system should be willing to pay for an
additional QALY. The ‘Benchmark ICER’ is an indicative cost-effectiveness threshold (in these analyses marked at $600; based
upon studies indicating this is a reasonable ICER for adult ART compared to no-ART). (b) The cost-effectiveness acceptability
curves (CEACs) show the probability (marked on the Y-axis) that LCM is cost-effective compared to CDM at alternative cost-
effectiveness thresholds (marked on the X-axis) based upon modelled variation in observed outcomes, under the different
scenarios. Two selected scenarios are: (a) LCM with CD4þ monitoring only; (b–e) LCM with CD4þ monitoring only and CD4þ
testing costs halved, for all trial participants and for age subgroups. Results show LCM is very unlikely to be cost-effective at
thresholds below $2000, except CD4þ testing for adolescents (aged 12þ), especially when testing costs are reduced.
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Table 4. Cost-effectiveness results for cotrimoxazole randomization (base case analyses and country sub-analyses).
Continue cotrimoxazole Stop cotrimoxazole Difference in means
Base case: Zimbabwe and Uganda results pools
Costs, mean (SD), US$ 926.5 (15.1) 947.3 (17.0) 20.7
QALYs, mean (SD) 1.87 (.00) 1.87 (.01) 0.01
Incremental cost-effectiveness ratio (ICER) Continue dominates
Country sub-analyses
Zimbabwe
Costs, mean (SD), US$ 1082.4 (30.1) 1100.6 (35.8) 18.2
QALYs, mean (SD) 1.88 (.00) 1.86 (.02) 0.02
Incremental cost-effectiveness ratio (ICER) Continue dominates
Uganda
Costs, mean (SD), US$ 875.3 (16.1) 896.2 (18.4) 20.9
QALYs, mean (SD) 1.87 (.00) 1.87 (.00) 0.00
Incremental cost-effectiveness ratio (ICER) Continue dominates
QALY, quality-adjusted life-year. Results are based uponmultiple imputation by chained equations using predictivemeanmatching, [9] where cost
and QALY data per period of analysis are missing assumed at random.provision of cotrimoxazole prophylaxis, for children
stabilized on long-term ART, was effective at reducing
hospitalizations and prescriptions of non-ART drugs
from malaria and other infections, resulting in health
gains and cost savings.
It is assumed the trial findings are generalizable to other
(non-trial) healthcare settings. Non-trial healthcare
facilities may struggle to achieve health outcomes as
good as those reported in the ARROW trial, which,
whilst designed as a pragmatic trial, was conducted in
centres which were mostly (3/4) already providing
paediatric ARTand had research capability. However, the
major concern is whether the incremental effectiveness of
alternatives in the ARROW trial is informative for
national-level policymaking. For the incremental effec-
tiveness of LCM compared to CDM to be greater in
non-trial settings than is reported in the ARROW trial,
non-trial healthcare centres would have to be able to
implement routine laboratory monitoring relatively more
successfully than managing patients clinically compared
to ARROW trial centres, which is unlikely.
For the monitoring randomization, analyses using all
ARROW trial data showed that LCM is ‘dominated’ by
CDM (being both more costly and less effective). This
result is likely due to chance since early outcome
differences could not have resulted from any differences in
management between the two arms [2]. Restricting to
outcomes beyond 12 weeks from randomization, or from
1 year, when excess disease progression/death in the
CDM arm became more evident, LCM offers some
benefits, but at considerable cost. Removing the costs of
routine toxicity monitoring, which was costly and offered
no health gains, and so should not be supported by
policymakers, led to lower estimates of the cost-per-
QALY gains (ICERs) resulting from LCM compared
to CDM.
Age sub-group analyses showed that LCM appears to
offer greatest value when targeted to children 12þ years Copyright © 2015 Wolters Kluwer Hold, and may even dominate CDM in this group if
provided without toxicity monitoring and assuming
lower future cost of CD4þ tests. This result is potentially
important: it likely reflects the greater treatment
adherence challenges observed among adolescents com-
pared with younger children, with routine CD4þ
monitoring being able to identify complete non-
adherence, which can be more easily concealed with
CDM.
There have been no previous studies investigating the
cost-effectiveness of paediatric ART monitoring
approaches in Africa [29]. Results from this study can
be compared to others investigating the cost-effectiveness
of laboratory monitoring for adults on ART. A cost-
effectiveness analysis of the DART trial, evaluating similar
strategies to those in the ARROW trial, showed LCM
was very unlikely to be cost-effective for adult patients
[6]. A combined analysis of three mathematical models,
investigating a wide range of monitoring alternatives, but
particularly focused on whether viral load monitoring
would be cost-effective, found that committing resources
to the expansion of ART coverage is likely to generate
greater health gains than more complex and expensive
monitoring approaches in most circumstances [30]. Viral
load monitoring was not investigated in the current study,
but the good health outcomes reported amongst children
in the ARROW trial mean that the potential for it to add
additional health gains (and hence be cost-effective)
is low.
Routine laboratory monitoring is recommended for
children in both Uganda and Zimbabwe. Until recently,
this has been using CD4þ and toxicity testing, but now
routine viral load monitoring is recommended [31,32].
However, programmatic data show that in practice
routine laboratory testing is not widely available and ART
is provided using an approach in effect equivalent to
CDM [19]. Similarly, cotrimoxazole prophlyaxis is not
available at many facilities [19]. There are then
distinctions between current ‘recommendations’ andealth, Inc. All rights reserved.
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inform policy so that it may suitably affect practice and be
expected to improve population health outcomes.
For the cotrimoxazole randomization, continued use of
cotrimoxazole prophylaxis was shown to offer health
gains and reduce health sector costs through reduced
infections, in both malaria-endemic Uganda, and in
non-malaria-endemic Harare, Zimbabwe. The policy
dilemma is not, therefore, whether contrimoxazole
should be continued – it should – but how much to
spend on implementation initiatives and health systems
strengthening to ensure its continued availability in
health centres.
The value of implementation analysis indicates health
systems should be willing to invest substantial amounts,
well beyond the cost of the drug itself, to ensure
availability of cotrimoxazole, suggesting efforts to
improve drug supply are likely to be of value. It also
highlights an important insight that health systems can
generate health gains for their populations, not only by
purchasing interventions, but also (and perhaps more so)
by identifying and determining how barriers to the
provision and receipt of those interventions can be
overcome. Further research in this direction is likely to
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